All In Biotech

Drug Trial Radar · NCT03755778

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Rifampin, and Quinidine on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jun 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Nov 29, 2018

Primary completion

Jan 21, 2019

Study completion Jan 27, 2019

Sponsor

Lead sponsor
Enanta Pharmaceuticals, IncIndustry
Sponsor type
Industry
Collaborators
Pharmaceutical Research Associates
First posted
Nov 28, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Rifampin, and Quinidine on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects

Conditions

  • RSV Infection

Interventions

  • EDP-938Drug

    Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 1)

  • EDP-938Drug

    Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 2)

  • EDP-938Drug

    Subjects will receive EDP-938 once daily on Day 1 and 8 (Part 3)

  • ItraconazoleDrug

    Subjects will receive itraconazole once daily from Day 5 to Day 18

  • RifampinDrug

    Subjects will receive rifampin once daily from Day 5 to Day 16

  • QuinidineDrug

    Subjects will receive quinidine once daily from Day 5 to Day 12

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax of EDP-938 with and without coadministration with itraconazoleTime frame: Up to 19 days
  2. AUC of EDP-938 with and without coadministration with itraconazoleTime frame: Up to 19 days
  3. Cmax of EDP-938 with and without coadministration with rifampinTime frame: Up to 17 days
  4. AUC of EDP-938 with and without coadministration with rifampinTime frame: Up to 17 days
  5. Cmax of EDP-938 with and without coadministration with quinidineTime frame: Up to 13 days
  6. AUC of EDP-938 with and without coadministration with quinidineTime frame: Up to 13 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaceutical Research Associates, Inc.,

    Lenexa, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.